Bildkälla: Stockfoto

Lipigon Q4 2022: Rights issue and Progress with Lipisense - Redeye

Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which renders a new Base Case.

Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which renders a new Base Case.
Börsvärldens nyhetsbrev
ANNONSER